Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Diabetes Association’s 68th Annual Scientific Sessions in San Francisco.
Peter Elliott, PhD, Senior Vice President of Development at Sirtris, will speak at the symposium titled Speed and Endurance, Nature or Nurture? His talk is on Sunday, June 8 beginning at 3:30 pm.
Sirtris will also give two poster presentations: Activation of the Protein Deacetylase SIRT1 Blunts Pro-Inflammatory Pathways in vivo; and Novel Small Molecule Activators of SIRT1 as a Therapeutic Approach to Type 2 Diabetes: The Identification of SRT100 as a Clinical Candidate. Both poster presentations will be on Sunday, June 8 beginning at noon.
Sirtris has announced positive Phase 1b clinical trial results with drug candidate SRT501, a proprietary formulation of resveratrol, in patients with Type 2 Diabetes. Sirtris has also developed new chemical entities (NCEs) that are chemically distinct from and more potent, in vitro, than resveratrol. The NCEs have been shown to lower glucose and improve insulin sensitivity in pre-clinical models of Type 2 Diabetes. These SIRT1 activators have the potential to be a frontline therapy for Type 2 Diabetes.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the aging process. Sirtris Pharmaceuticals is engaged in human clinical trials for Type 2 Diabetes, and is planning similar trials in cancer, another age-related disease. Sirtris is also engaged in a human clinical trial for MELAS, a mitochondrial disorder. The company’s headquarters are in Cambridge, Massachusetts. On June 2, 2008, GlaxoSmithKline plc announced the successful completion by an indirect wholly-owned subsidiary of a tender offer to purchase all of the outstanding shares of Sirtris common stock. Approximately 97% of Sirtris's outstanding shares were tendered in the offer.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the potential therapeutic effects of SIRT1 activators including NCEs for diseases of aging, such as Type 2 Diabetes; the success of SIRT1 activators as therapies for diseases, such as Type 2 Diabetes; the progress and results of preclinical and clinical studies of SIRT1 activators, such as SRT501 and Sirtris’ NCEs; and the potential of sirtuin modulators to receive regulatory approval. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company’s product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company’s potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company’s product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company’s product candidates, and those other risks factors that can be found in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.